Rolan P E, Phillips S, Adams J, Posner J
Department of Clinical Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, UK.
Eur J Clin Pharmacol. 1990;39(3):311-3. doi: 10.1007/BF00315119.
The onset of effect of acrivastine, a new H1-antagonist, has been assessed using antagonism of histamine-induced bronchoconstriction in sensitive volunteers. Acrivastine administered 30, 45, 60 or 90 min before challenge produced a right-shift of the histamine dose-response curve of at least 8-fold indicating that a clinically desired degree of H1-antagonism was present within 30 min of ingestion of the recommended therapeutic dose.
已通过在敏感志愿者中对抗组胺诱导的支气管收缩作用，评估了新型H1拮抗剂阿伐斯汀的起效时间。在激发试验前30、45、60或90分钟给予阿伐斯汀，可使组胺剂量反应曲线右移至少8倍，这表明在摄入推荐治疗剂量后30分钟内即出现了临床上所需程度的H1拮抗作用。
